It’s been an eventful and promising year for pharma. The eyeforpharma team choose their top five pharma news stories of 2014.Globally, healthcare is high on citizens’ and policy-makers’ agendas and, wherever healthcare and business intersect, we find controversy. Indeed, this year, pharma has hardly seemed to be out of the headlines, becoming part of the international news agenda on several […]
istockphotoThree-year annualized return: 28.1%Annual expense ratio: 0.35%Minimum initial investment: $3,000Biggest holdings: Actavis, Merck, Bristol-Myers Squibb, UnitedHealth Group, AstraZenecaVanguard Health Care (VGHCX) is the Grand Pooh-Bah of health care sector funds. Not only is it the biggest, it also charges the least of any health care mutual fund (exchange-traded funds tend to cost less). What’s more, even as Vanguard Health outpaced […]
Benchmarks ended a narrow trading session in the green on Monday, boosted by gains in Internet, bio-tech and small-cap stocks. However, developments on the deals front were mixed, limiting the Dow’s gains. While AT&T agreed to acquire DirecTV, Pfizer’s final bid was rejected by AstraZeneca. As the day was devoid of any major economic data, investors focused their attention on […]
Benchmarks finished Monday’s choppy run mostly higher as investor sentiment following new deals in the health care sector, positive pending home sales data and intense selling pressure on internet stocks. While merger and acquisition activity in the health care sector helped the S&P 500 and Dow close in the green, the Nasdaq ended in negative territory due to decline in […]
